NextCure, Inc. (NXTC) Misses Q2 EPS by 17c

NextCure, Inc. (NASDAQ: NXTC) reported Q2 EPS of ($0.55), $0.17 worse than the analyst estimate of ($0.38).

For earnings history and earnings-related data on NextCure, Inc. (NXTC) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Boost Run posts Q2 revenue of $31.1M, up 270% year over year
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79